Clients

OncoSec Medical Inc.

Company Snapshot: OncoSec Medical Inc.

ONCS
Last Change Volume High Low

Company Overview

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches.

Featured Documents

Client News

  1. Jul 17 2018 OncoSec Presents Update from Triple Negative Breast Cancer Program at 3rd Global Insight Conference on Breast Cancer
  2. Jul 16 2018 OncoSec Appoints Sara M. Bonstein as Chief Financial Officer and Chief Operating Officer
  3. Jun 28 2018 OncoSec Provides Outlook for Second Half of 2018
  4. Jun 25 2018 OncoSec Added to the Russell Microcap® Index